Document is current
Any future updates will be listed below
-
Authors
Blumental, Sophie https://orcid.org/0000-0003-4460-3420
Lajot, Adrien
Vandromme, Mathil
Lafort, Yves
Dockx, Yinthe
Denayer, Sarah
Wampers, Alicia
Nebbioso, Andrea
Tilmanne, Anne
Mignon, Celine
Tuerlinckx, David
Rigolle, Hanne
Matthijs, Inge
Vandersnickt, Jan
Hellinckx, Johan
Dewulf, Jonas
Coppens, Katrien
Van Hoorenbeeck, Kim
Vanlede, Koen
Winters, Lore
Seyler, Lucie
Parsy, Marie-Pierre
Reynders, Marijke
Balcaen, Mathilde
Urbina, Montse
Dauby, Nicolas
Chatzis, Olga
Naesens, Reinout
Dorval, Sarah
Ternest, Silke
Vanspeybroeck, Sophie
Goetghebuer, Tessa
Van Ackere, Tine
Selimaj Kontoni, Valbona
El Bitar, Wassim
Holemans, Xavier
Bruyere, Yveline
Van Brusselen, Daan
De Mot, Laurane
Raes, Marc
-
Funding
Funding for this research was provided by:
Care Fundation Chirec
Belgian Federal Public Service ‘Health, Food Chain Safety, and Environment
European Centre for Disease Prevention and Control (Framework Contract ECDC/2021/016 (VEBIS project))
European Union (BE-SURVID project).
- License Information
-
More Information
Article History
Received: 21 December 2025
Accepted: 20 April 2026
First Online: 20 May 2026
Declarations
Ethics approval and consent to participate: Both study protocols were approved by ethics committees of participating hospitals. For the SARI surveillance, approval from a coordinating central ethical committee was also obtained (Ref: B.U.N. 143201215671). No informed consent was requested for the RSV Ped survey due to its retrospective design. The whole study was conducted in compliance with the principles of GCP and in accordance with all applicable regulatory requirements.
Consent for publication: Not Applicable (no identifying images or other personal or clinical details of participants that compromise anonymity in our survey).
Use of AI: ChatGPT was used to generate portions of the code for data management and statistical analysis (R Software). After using this tool, AL reviewed and edited the content as needed and takes full responsibility for the final version of the article.
Competing interests: AL, MV, YL, YD, SD, AW, AN, AT, CM, DT, HR, IM, JV, JH, JD, KC, KVH, KV, LW, MB, MP, MU, OC, SD, ST, SV, TV, VSK, XH, and YB have no conflict of interest to declare. SB has taken part to one advisory board of VIATRIS (outside the scope of this work) and has been speaker for Mediquality. MR and TG have received honoraria from Sanofi, MSD and GSK for taking part in advisory boards and expert meetings and for acting as a speaker in congresses. DVB has received honoraria from Sanofi, MSD and Pfizer for taking part in advisory boards and expert meetings. TG has been clinical investigator in a nirsevimab clinical trial. N.D had honoraria from MSD for advisory board; speaker fees from Abbvie, Mediquality and Astra Zeneca (outside the scope of this work), travel fees and research grant from MSD. travel fees from Gilead and ViiV Healthcare, WEB is MSD global international speaker outside of the scope of the submitted work and participated to MSD EMA HPV advisory board. MRE has received travel grant from Pfizer.
